Immuneering Corporation
IMRX
$5.02
$0.173.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.70% | 4.27% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.90% | 11.51% | |||
| Operating Income | -23.90% | -11.51% | |||
| Income Before Tax | -28.30% | -16.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -28.30% | -16.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.30% | -16.24% | |||
| EBIT | -23.90% | -11.51% | |||
| EBITDA | -24.02% | -11.54% | |||
| EPS Basic | -28.19% | -16.12% | |||
| Normalized Basic EPS | -24.48% | -17.96% | |||
| EPS Diluted | -28.19% | -16.12% | |||
| Normalized Diluted EPS | -24.48% | -17.96% | |||
| Average Basic Shares Outstanding | 0.06% | 0.11% | |||
| Average Diluted Shares Outstanding | 0.06% | 0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||